TITLE

Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development

AUTHOR(S)
Shoji, Y.; Takohashi, M.; Kitamura, T.; Watanobe, K.; Kawamori, T.; Maruyama, T.; Sugimoto, Y.; Negishi, M.; Narumiya, S.; Sugimura, T.; Wakabayashi, K.
PUB. DATE
August 2004
SOURCE
Gut;Aug2004, Vol. 53 Issue 8, p1151
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: Involvement of prostaglandin E2 (PGE2) receptors EP1, ER2, and EP4 in the formation of aberrant crypt foci (ACF) and/or intestinal polyps has been suggested. In contrast, EP3 appears to have no influence on the early stages of colon carcinogenesis. In the present study, we examined expression of PGE2 receptor subtypes EP1, EP2, EP3, and EP4 in normal colon mucosa and colon cancers, and assessed the contribution of EP3 to colon cancer development. Methods: mRNA expression of PGE2 receptor subtypes EP1, EP2, EP3, and EP4 in normal colon mucosa and colon cancers in azoxymethane (AOM) treated mice and rats, and in humans, were examined by reverse transcription-polymerase chain reaction (RT-PCR), quantitative real time RT-PCR, and immunohistochemical analyses. Evaluation of the role of EP3 was performed by intraperitoneal injection of AOM, using EP3 receptor knockout mice. Effects of EP3 receptor activation on cell growth of human colon cancer cell lines were examined using ONO-AE-248, an EP3 selective agonist. Moreover, EP3 expression in colon cancer cell lines was analysed with or without 5-aza-2'-deoxycytidine (5-aza-dC) treatment. Results: Expression levels of ER1 and EP2 mRNA were increased in cancer tissues. EP4 mRNA was constantly expressed in normal mucosa and cancers. In contrast, expression of EP3 mRNA was markedly decreased in colon cancer tissues, being 5% in mice, 9% in rats, and 28% in humans compared with normal colon mucosa, analysed by quantitative real time RT-PCR. Immunohistochemical staining demonstrated the rat EP3 receptor protein to be expressed in epithelial cells of normal mucosa and some ports of small carcinomas but hardly detectable in large carcinomas of the colon. Colon cancer development induced by AOM in EP3 receptor knockout mice was enhanced compared with wild-type mice, with a higher incidence of colon tumours (78% v 57%) and mean number of tumours per mouse I (2.17 (0.51) v 0.75 (0.15); p<.05). Expression of EP3 mRNA was detected in only one of 11 human colon cancer cell lines tested. Treatment with 5 μM of an EP3 selective agonist, ONO-AE-248, resulted in a 30% decrease in viable cell numbers in the HCA-7 human colon cancer cell line in which ER3 was expressed. Treatment with 5-aza-dC restored EP3 expression in CACO-2, CW-2, and DLD- 1 cells but not in WiDr cells, suggesting involvement of hypermethylation in the downregulation of ER3 to some extent. Conclusion: The PGE2 receptor subtype EP3 plays an important role in suppression of cell growth and its downregulation enhances colon carcinogenesis at a later stage. Hypermethylation of the EP3 receptor gene could occur and may contribute towards downregulating EP3 expression to some extent in colon cancers.
ACCESSION #
13986668

 

Related Articles

  • The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE2 signalling in colorectal adenoma cells. Greenhough, A.; Wallam, C. A.; Hicks, D. J.; Moorghen, M.; Williams, A. C.; Paraskeva, C. // Oncogene;6/10/2010, Vol. 29 Issue 23, p3398 

    Overexpression of cyclooxygenase-2 (COX-2) and elevated levels of its enzymatic product prostaglandin E2 (PGE2) occur in the majority of colorectal cancers and have important roles in colorectal tumorigenesis. However, despite the established prosurvival role of PGE2 in cancer, the underlying...

  • Pro-Apoptotic PUMA and Anti-Apoptotic Phospho-BAD Are Highly Expressed in Colorectal Carcinomas. Mi Kim; Eun Jeong; Boa Chae; Jong Lee; Young Soung; Suk Nam; Jung Lee; Nam Yoo // Digestive Diseases & Sciences;Oct2007, Vol. 52 Issue 10, p2751 

    Abstract  Several lines of evidence indicate that, together with deregulated growth, alteration of apoptosis plays a pivotal role in tumorigenesis. PUMA, a pro-apoptotic member of Bcl-2 family, mediates p53-dependent and -independent apoptosis. BAD is also a pro-apoptotic Bcl-2...

  • Early Carcinogenic Events in HNPCC Adenomas: Differences with Sporadic Adenomas. Fleur Rijcken; Jan Koornstra; Tineke van der Sluis; Wytske Boersma-van Ek; Jan Kleibeuker; Harry Hollema // Digestive Diseases & Sciences;Jun2008, Vol. 53 Issue 6, p1660 

    Abstract   Background Tumorigenesis in hereditary nonpolyposis colorectal cancer (HNPCC) differs from that in sporadic colorectal cancer during the early stage. We examined the expression of proliferation- and apoptosis-regulating proteins in relation to proliferation and apoptosis in...

  • The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Alexander Greenhough; Helena J.M. Smartt; Amy E. Moore; Heather R. Roberts; Ann C. Williams; Christos Paraskeva; Abderrahmane Kaidi // Carcinogenesis;Mar2009, Vol. 30 Issue 3, p377 

    It is widely accepted that alterations to cyclooxygenase-2 (COX-2) expression and the abundance of its enzymatic product prostaglandin E2 (PGE2) have key roles in influencing the development of colorectal cancer. Deregulation of the COX-2/PGE2 pathway appears to affect colorectal tumorigenesis...

  • Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Hawcroft, G.; Ko, C. W. S.; Hull, M. A. // Oncogene;5/10/2007, Vol. 26 Issue 21, p3006 

    The predominant product of cyclooxygenase (COX) activity in the colon, prostaglandin (PG) E2 promotes intestinal tumorigenesis. Expression of the PGE2 receptor EP4 is upregulated during colorectal carcinogenesis. Therefore, we investigated the role of elevated PGE2-EP4 receptor signalling in the...

  • Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer. Toon, Christopher W.; Chou, Angela; Clarkson, Adele; DeSilva, Keshani; Houang, Michelle; Chan, Joseph C. Y.; Sioson, Loretta L.; Jankova, Lucy; Gill, Anthony J. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    MYC over-expression as determined by molecular means has been reported as a favorable prognostic biomarker in colorectal carcinoma (CRC). However MYC expression analysis is not available in the routine clinical setting. We investigated whether immunohistochemistry (IHC) for the myc protein using...

  • Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Brudvik, Kristoffer; Henjum, Karen; Aandahl, Einar; Bjørnbeth, Bjørn; Taskén, Kjetil // Cancer Immunology, Immunotherapy;Jul2012, Vol. 61 Issue 7, p1045 

    Adaptive regulatory T cells (Tregs) contribute to an immunosuppressive microenvironment in colorectal cancer (CRC). Here, we examined whether the level of Treg-mediated inhibition of antitumor immune responses in patients with metastatic CRC (metCRC) selected for liver resection is associated...

  • Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. Rengucci, Claudia; De Maio, Giulia; Gardini, Andrea Casadei; Zucca, Mattia; Scarpi, Emanuela; Zingaretti, Chiara; Foschi, Giovanni; Tumedei, Maria Maddalena; Molinari, Chiara; Saragoni, Luca; Puccetti, Maurizio; Amadori, Dino; Zoli, Wainer; Calistri, Daniele // Journal of Experimental & Clinical Cancer Research (17569966);2014, Vol. 33 Issue 1, p1 

    Background Epigenetic alterations of specific genes have been reported to be related to colorectal cancer (CRC) transformation and would also appear to be involved in the early stages of colorectal carcinogenesis. Little data are available on the role of these alterations in determining a...

  • PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Nassif, Najah T.; Lobo, Glenn P.; Xiaojuan Wu; Henderson, Christopher J. A.; Morrison, Carl D .; Eng, Charis; Jalaludin, Bin; Segelov, Eva // Oncogene;1/15/2004, Vol. 23 Issue 2, p617 

    The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a dual-specificity phosphatase that negatively regulates the phosphatidylinositol 3'-kinase (PI3?K)/Akt-dependent cellular survival pathway. PTEN is frequently inactivated in many tumour types including...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics